Cargando…

Vasculitis: From Target Molecules to Novel Therapeutic Approaches

Systemic vasculitis is a group of diverse diseases characterized by immune-mediated inflammation of blood vessels. Current treatments for vasculitis, such as glucocorticoids and alkylating agents, are associated with significant side effects. In addition, the management of both small and large vesse...

Descripción completa

Detalles Bibliográficos
Autor principal: Chung, Sang-Wan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301353/
https://www.ncbi.nlm.nih.gov/pubmed/34209028
http://dx.doi.org/10.3390/biomedicines9070757
_version_ 1783726648861917184
author Chung, Sang-Wan
author_facet Chung, Sang-Wan
author_sort Chung, Sang-Wan
collection PubMed
description Systemic vasculitis is a group of diverse diseases characterized by immune-mediated inflammation of blood vessels. Current treatments for vasculitis, such as glucocorticoids and alkylating agents, are associated with significant side effects. In addition, the management of both small and large vessel vasculitis is challenging due to a lack of robust markers of disease activity. Recent research has advanced our understanding of the pathogenesis of both small and large vessel vasculitis, and this has led to the development of novel biologic therapies capable of targeting key cytokine and cellular effectors of the inflammatory cascade. It is anticipated that these novel treatments will lead to more effective and less toxic treatment regimens for patients with systemic vasculitis.
format Online
Article
Text
id pubmed-8301353
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83013532021-07-24 Vasculitis: From Target Molecules to Novel Therapeutic Approaches Chung, Sang-Wan Biomedicines Review Systemic vasculitis is a group of diverse diseases characterized by immune-mediated inflammation of blood vessels. Current treatments for vasculitis, such as glucocorticoids and alkylating agents, are associated with significant side effects. In addition, the management of both small and large vessel vasculitis is challenging due to a lack of robust markers of disease activity. Recent research has advanced our understanding of the pathogenesis of both small and large vessel vasculitis, and this has led to the development of novel biologic therapies capable of targeting key cytokine and cellular effectors of the inflammatory cascade. It is anticipated that these novel treatments will lead to more effective and less toxic treatment regimens for patients with systemic vasculitis. MDPI 2021-06-30 /pmc/articles/PMC8301353/ /pubmed/34209028 http://dx.doi.org/10.3390/biomedicines9070757 Text en © 2021 by the author. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Chung, Sang-Wan
Vasculitis: From Target Molecules to Novel Therapeutic Approaches
title Vasculitis: From Target Molecules to Novel Therapeutic Approaches
title_full Vasculitis: From Target Molecules to Novel Therapeutic Approaches
title_fullStr Vasculitis: From Target Molecules to Novel Therapeutic Approaches
title_full_unstemmed Vasculitis: From Target Molecules to Novel Therapeutic Approaches
title_short Vasculitis: From Target Molecules to Novel Therapeutic Approaches
title_sort vasculitis: from target molecules to novel therapeutic approaches
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301353/
https://www.ncbi.nlm.nih.gov/pubmed/34209028
http://dx.doi.org/10.3390/biomedicines9070757
work_keys_str_mv AT chungsangwan vasculitisfromtargetmoleculestonoveltherapeuticapproaches